KR100925835B1 - 리세드로네이트 나트륨 무수물 및 수화물의 제조방법 - Google Patents
리세드로네이트 나트륨 무수물 및 수화물의 제조방법 Download PDFInfo
- Publication number
- KR100925835B1 KR100925835B1 KR1020070126592A KR20070126592A KR100925835B1 KR 100925835 B1 KR100925835 B1 KR 100925835B1 KR 1020070126592 A KR1020070126592 A KR 1020070126592A KR 20070126592 A KR20070126592 A KR 20070126592A KR 100925835 B1 KR100925835 B1 KR 100925835B1
- Authority
- KR
- South Korea
- Prior art keywords
- risedronate sodium
- hydrate
- hours
- monohydrate
- reflux
- Prior art date
Links
- 229960000759 risedronic acid Drugs 0.000 title claims abstract description 32
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 title claims abstract description 30
- 238000004519 manufacturing process Methods 0.000 title claims description 14
- HYFDYHPNTXOPPO-UHFFFAOYSA-L disodium;hydroxy-(1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphinate;pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].OP(=O)(O)C(P(O)([O-])=O)(O)CC1=CC=CN=C1.OP(=O)(O)C(P(O)([O-])=O)(O)CC1=CC=CN=C1 HYFDYHPNTXOPPO-UHFFFAOYSA-L 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 48
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 31
- 238000010992 reflux Methods 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 22
- 238000001816 cooling Methods 0.000 claims description 20
- 239000002904 solvent Substances 0.000 claims description 19
- 229940026196 risedronate sodium monohydrate Drugs 0.000 claims description 15
- KLQNARDFMJRXSF-UHFFFAOYSA-M sodium;hydroxy-(1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphinate;hydrate Chemical compound O.[Na+].OP(=O)(O)C(P(O)([O-])=O)(O)CC1=CC=CN=C1 KLQNARDFMJRXSF-UHFFFAOYSA-M 0.000 claims description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 9
- -1 risedronate sodium anhydride Chemical class 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims description 3
- 238000010792 warming Methods 0.000 claims 1
- 239000007858 starting material Substances 0.000 abstract description 8
- 150000004677 hydrates Chemical class 0.000 abstract description 5
- 208000001132 Osteoporosis Diseases 0.000 abstract description 3
- 229940089617 risedronate Drugs 0.000 abstract description 3
- 239000011734 sodium Substances 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract 1
- 150000004682 monohydrates Chemical class 0.000 description 22
- 238000002411 thermogravimetry Methods 0.000 description 22
- 239000013078 crystal Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 238000002441 X-ray diffraction Methods 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- 150000008064 anhydrides Chemical class 0.000 description 4
- 238000000634 powder X-ray diffraction Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229940122361 Bisphosphonate Drugs 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 2
- 150000004663 bisphosphonates Chemical class 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000001757 thermogravimetry curve Methods 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000015202 calcium metabolic disease Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 150000004686 pentahydrates Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000010956 selective crystallization Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
용매 %/물(v/v) | 반응시간 | 반응온도 | KF% | TGA% | XRD | 수율% |
EtOH 50% | 19 | 환류 | 5.1 | 6.7 | 1수화물 | 95.4 |
EtOH 50% | 7 | 60℃ | 8.5 | 9.9 | 1.5수화물 | 97.0 |
EtOH 60% | 7 | 환류 | 5.4 | 7.2 | 1수화물 | 97.5 |
EtOH 70% | 5 | 환류 | 4.7 | 7.2 | 1수화물 | 99.7 |
EtOH 80% | 5 | 환류 | 5.6 | 7.4 | 1수화물 | 99.7 |
IPA 60% | 7 | 환류 | 5.2 | 7.2 | 1수화물 | 95.4 |
IPA 60% | 7 | 60℃ | 8.6 | 10.0 | 1.5수화물 | 97.0 |
IPA 70% | 6 | 환류 | 4.8 | 7.3 | 1수화물 | 98.2 |
IPA 80% | 7 | 환류 | 4.6 | 7.4 | 1수화물 | 97.5 |
MeOH 40% | 5 | 환류 | 5.3 | 6.9 | 1수화물 | 95.4 |
MeOH 50% | 5 | 환류 | 4.8 | 7.1 | 1수화물 | 95.4 |
MeOH 60% | 5 | 환류 | 4.9 | 7.2 | 1수화물 | 97.5 |
MeOH 60% | 7 | 60℃ | 8.6 | 10.1 | 1.5수화물 | 97.5 |
MeOH 70% | 5 | 환류 | 5.1 | 7.1 | 1수화물 | 97.5 |
MeOH 80% | 6 | 환류 | 5.1 | 7.3 | 1수화물 | 99.7 |
MeOH 90% | 5 | 환류 | 5.0 | 7.4 | 1수화물 | 99.7 |
MeOH 100% | 12 | 환류 | 0.09 | 0.33 | 무수물 | 96.4 |
ACN 60% | 3 | 환류 | 5.2 | 7.4 | 1수화물 | 97.5 |
ACN 80% | 6 | 환류 | 5.7 | 7.3 | 1수화물 | 98.8 |
Dioxane 70% | 3 | 환류 | 4.7 | 7.1 | 1수화물 | 97.5 |
Claims (10)
- 하기의 단계를 포함하는 리세드로네이트 나트륨 1수화물의 제조방법.a) 리세드로네이트 나트륨 2.5수화물에 에탄올, 메탄올, 이소프로판올, 아세토니트릴 및 1,4-디옥산 중에서 선택되는 1종의 용매와 물의 6:4 내지 9:1비율 혼합용매를 가하고;b) 환류 온도에서 3 내지 7시간 교반하고;c) 냉각하고 여과 후 건조하여 리세드로네이트 나트륨 1수화물을 제조하는 방법.
- 제1항에 있어서, 단계 (a)에서의 용매가 에탄올 또는 이소프로판올임을 특징으로 하는 리세드로네이트 나트륨 1수화물의 제조방법.
- 제1항에 있어서, 단계 (a)에서의 용매와 물의 혼합비율이 7:3임을 특징으로 하는 리세드로네이트 나트륨 1수화물의 제조방법.
- 제1항에 있어서, 단계 (b)에서의 환류 시간이 5시간임을 특징으로 하는 리세드로네이트 나트륨 1수화물의 제조방법.
- 하기의 단계를 포함하는 리세드로네이트 나트륨 1.5수화물의 제조방법.a) 리세드로네이트 나트륨 2.5수화물에 이소프로판올과 물의 5:5 내지 6:4 비율 혼합용매를 가하고;b) 50℃ 내지 70℃로 가온하여 6시간 내지 8시간교반하고;c) 냉각하고 여과 후 열풍 건조하여 리세드로네이트 나트륨 1.5수화물을 제조하는 방법.
- 삭제
- 제5항에 있어서 단계 (a)에서의 이소프로판올과 물의 비율이 6:4 임을 특징으로 하는 리세드로네이트 나트륨 1.5수화물의 제조방법.
- 제5항에 있어서 단계 (b)에서의 반응 온도가 60℃이고, 반응 시간이 7시간임을 특징으로 하는 리세드로네이트 나트륨 1.5수화물의 제조방법.
- 하기의 단계를 포함함을 특징으로 하는 리세드로네이트 나트륨 무수물의 제조방법.a) 리세드로네이트 나트륨 2.5수화물에 메탄올을 가하고;b) 환류 온도에서 7시간 내지 20시간 교반하고;c) 냉각하고 여과 후 건조하여 리세드로네이트 나트륨 무수물을 제조하는 방 법.
- 제9항에 있어서 단계 (b)에서의 환류 시간이 12시간임을 특징으로 하는 리세드로네이트 나트륨 무수물의 제조방법.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070126592A KR100925835B1 (ko) | 2007-12-07 | 2007-12-07 | 리세드로네이트 나트륨 무수물 및 수화물의 제조방법 |
JP2010536837A JP2011506310A (ja) | 2007-12-07 | 2008-11-24 | 無水及び水和物形態のリセドロン酸ナトリウムを製造する方法 |
EP08857936A EP2229397A4 (en) | 2007-12-07 | 2008-11-24 | PROCESS FOR THE PRODUCTION OF RISEDRONATNATRIUM AS WATER-FREE FORMS AND HYDRATFORMS |
PCT/KR2008/006912 WO2009072769A2 (en) | 2007-12-07 | 2008-11-24 | Process for preparing risedronate sodium as anhydrous and hydrate forms |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070126592A KR100925835B1 (ko) | 2007-12-07 | 2007-12-07 | 리세드로네이트 나트륨 무수물 및 수화물의 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20090059635A KR20090059635A (ko) | 2009-06-11 |
KR100925835B1 true KR100925835B1 (ko) | 2009-11-06 |
Family
ID=40718330
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020070126592A KR100925835B1 (ko) | 2007-12-07 | 2007-12-07 | 리세드로네이트 나트륨 무수물 및 수화물의 제조방법 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2229397A4 (ko) |
JP (1) | JP2011506310A (ko) |
KR (1) | KR100925835B1 (ko) |
WO (1) | WO2009072769A2 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0710421A2 (pt) | 2006-05-11 | 2011-08-09 | Ind Swift Ltd | processo para a preparação de ácido risedrÈnico puro ou sais |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020071976A (ko) * | 2000-02-01 | 2002-09-13 | 더 프록터 앤드 갬블 캄파니 | 헤미펜타히드레이트 또는 모노히드레이트로서의3-피리딜-1-히드록시에틸리덴-1,1-비스포스폰산 나트륨의선택적 결정화 방법 |
KR20040101447A (ko) * | 2002-04-11 | 2004-12-02 | 테바 파마슈티컬 인더스트리즈 리미티드 | 리세드로네이트 나트륨의 신규한 동질이상체 및유사동질이상체 |
JP2006511489A (ja) | 2002-10-25 | 2006-04-06 | ツェンティバ,エー.エス | 3−ピリジル−1−ヒドロキシエチリデン−1,1−ビスホスホン酸のナトリウム塩の新規な結晶形態 |
KR20080030515A (ko) * | 2006-09-28 | 2008-04-04 | 플레밍 레보레이토리스 리미티드 | 3-피리딜-1-히드록시에틸리딘-1,1-비스포스폰산 나트륨염의순수한 다형체 제조방법 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1775302A1 (en) * | 2005-10-11 | 2007-04-18 | Sandoz A/S | Method for preparing crystalline sodium risedronate |
-
2007
- 2007-12-07 KR KR1020070126592A patent/KR100925835B1/ko active IP Right Grant
-
2008
- 2008-11-24 WO PCT/KR2008/006912 patent/WO2009072769A2/en active Application Filing
- 2008-11-24 JP JP2010536837A patent/JP2011506310A/ja active Pending
- 2008-11-24 EP EP08857936A patent/EP2229397A4/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020071976A (ko) * | 2000-02-01 | 2002-09-13 | 더 프록터 앤드 갬블 캄파니 | 헤미펜타히드레이트 또는 모노히드레이트로서의3-피리딜-1-히드록시에틸리덴-1,1-비스포스폰산 나트륨의선택적 결정화 방법 |
KR20040101447A (ko) * | 2002-04-11 | 2004-12-02 | 테바 파마슈티컬 인더스트리즈 리미티드 | 리세드로네이트 나트륨의 신규한 동질이상체 및유사동질이상체 |
JP2006511489A (ja) | 2002-10-25 | 2006-04-06 | ツェンティバ,エー.エス | 3−ピリジル−1−ヒドロキシエチリデン−1,1−ビスホスホン酸のナトリウム塩の新規な結晶形態 |
KR20080030515A (ko) * | 2006-09-28 | 2008-04-04 | 플레밍 레보레이토리스 리미티드 | 3-피리딜-1-히드록시에틸리딘-1,1-비스포스폰산 나트륨염의순수한 다형체 제조방법 |
Also Published As
Publication number | Publication date |
---|---|
JP2011506310A (ja) | 2011-03-03 |
WO2009072769A3 (en) | 2009-08-27 |
WO2009072769A2 (en) | 2009-06-11 |
KR20090059635A (ko) | 2009-06-11 |
EP2229397A4 (en) | 2012-03-21 |
EP2229397A2 (en) | 2010-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100775440B1 (ko) | 리세드로네이트 나트륨 헤미펜타히드레이트의 제조방법 | |
KR20140023949A (ko) | 결정형의 졸레드로닉산, 이의 제조방법 및 이를 포함하는 약학 조성물 | |
US8030480B2 (en) | Cost-effective process for preparation of manufacture of iron sucrose | |
KR20120005466A (ko) | 7―[(3r,4r)―3―하이드록시―4―하이드록시메틸―피롤리딘―1―일메틸]―3,5―디하이드로―피롤로[3,2―d]피리미딘―4―온의 유용한 약학적 염 | |
JP2008543974A (ja) | ペメトレキセド二酸の結晶形およびその調製方法 | |
JP7444914B2 (ja) | カルコブトロールの変態aの結晶形態を製造する方法 | |
KR100925835B1 (ko) | 리세드로네이트 나트륨 무수물 및 수화물의 제조방법 | |
WO2010104113A1 (ja) | 多面体状遷移金属錯体、超微粒子内包遷移金属錯体およびその製造方法 | |
KR20010080927A (ko) | 8-시아노-1-사이클로프로필-7-(1s,6s-2,8-디아자비사이클로[4.3.0]노난-8-일)-6-플루오로-1,4-디하이드로-4-옥소-3-퀴놀린 카복실산의 결정 개질체 b | |
Espina et al. | Reaction of π-Ti2O (PO4) 2· 2H2O with molten alkali nitrates: Synthesis of the fibrous materials π-M0. 5H0. 5TiOPO4 (M= Na, K) | |
KR100961822B1 (ko) | 3-피리딜-1-히드록시에틸리딘-1,1-비스포스폰산 나트륨염의순수한 다형체 제조방법 | |
CN109775715B (zh) | 一种无氟合成晶粒尺寸均匀的AlPO4-34分子筛的方法 | |
WO2007026379A2 (en) | Novel crystalline forms of risedronate monosodium | |
RU2786716C2 (ru) | Способ получения кристаллической формы модификации a калкобутрола | |
KR100812528B1 (ko) | 리세드로네이트 나트륨염의 헤미펜타히드레이트의 선택적결정화방법 | |
KR20010066897A (ko) | 결정성 파미드론산 이나트륨염 수화물과 그의 제조방법 | |
KR20240057364A (ko) | 다이메틸-2,3-다이하이드로-1h-인덴 유도체의 신규 염 및 이의 제조방법 | |
CN112574219A (zh) | 一种苯并咪唑并嘧啶酮衍生物的合成方法 | |
KR100828705B1 (ko) | 리세드론산 나트륨 수화물의 제조방법 | |
JPH05230044A (ja) | ピレタニドの新規な結晶多形 | |
CN118184660A (zh) | 一种苯并二氮杂䓬化合物的盐、盐的晶型、制备方法及用途 | |
KR100878034B1 (ko) | 결정상 리세드로네이트 모노소듐 모노하이드레이트 및 이의제조방법 | |
CN116283797A (zh) | 一种噁拉戈利钠的合成方法 | |
WO2009034580A1 (en) | Improved process for the preparation of risedronate sodium hemipentahydrate | |
JP2020007252A (ja) | エスゾピクロンジベンゾイル−d−酒石酸塩の製造方法、エスゾピクロンの製造方法、及びエスゾピクロンジベンゾイル−d−酒石酸塩の結晶 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120920 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20131202 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20141103 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20151202 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20161102 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20171102 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20191031 Year of fee payment: 11 |
|
R401 | Registration of restoration |